Success Metrics

Clinical Success Rate

33.3%

Based on 1 completed trials

Completion Rate

33%(1/3)

Active Trials

0(0%)

Results Posted

100%(1 trials)

Terminated

2(67%)

Phase Distribution

Ph phase_1

100%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution3 total trials

Phase 1Safety & dosage

3(100.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

33.3%

1 of 3 finished

Non-Completion Rate

66.7%

2 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(1)

Terminated(2)

Detailed Status

Terminated2

Completed1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

33.3%

Most Advanced

Phase 1

Trials by Phase

Phase 13 (100.0%)

Trials by Status

completed133%

terminated267%

Recent Activity

0 active trials

Showing 3 of 3

terminatedphase_1

Biodistribution Study of CMD-193 in Patients With Advanced Tumours Expressing the Lewis-Y Antigen

NCT00293215

completedphase_1

Study Evaluating CMD-193 in Advanced Malignant Solid Tumors

NCT00161642

terminatedphase_1

Study Evaluating Intravenous CMD-193 in Subjects With Advanced Malignant Solid Tumors

NCT00257881

Clinical Trials (3)

Showing 3 of 3 trials

NCT00293215Phase 1

Biodistribution Study of CMD-193 in Patients With Advanced Tumours Expressing the Lewis-Y Antigen

Terminated

NCT00161642Phase 1

Study Evaluating CMD-193 in Advanced Malignant Solid Tumors

Completed

NCT00257881Phase 1

Study Evaluating Intravenous CMD-193 in Subjects With Advanced Malignant Solid Tumors

Terminated

All 3 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 3